

Supplementary Table 1. Changes in FPG, lipid profiles, body weight, and blood pressure after 12 weeks of treatment with sodium-glucose co-transporter-2 inhibitors as add-on therapy

Variable	Baseline	Week 12	LS mean change from baseline (95% CI)	Difference in LS mean change (95% CI) ^a
FPG, mg/dL				
Add-on (<i>n</i> =207)	164.8±2.9	128.5±2.2	-30.3 (-34.6 to -26.1) ^b	-
MET (<i>n</i> =58)	159.2±4.0	132.3±2.5	-31.1 (-39.0 to -23.2) ^b	-
MET+SU (<i>n</i> =19)	161.5±6.8	133.1±4.9	-30.9 (-44.7 to -17.1) ^b	-0.2 (-21.7 to 21.3)
MET+SU+DPP4i (<i>n</i> =52)	172.0±4.9	131.8±4.3	-34.7 (-43.1 to -26.4) ^b	3.6 (-12.0 to 19.3)
Insulin (<i>n</i> =78)	164.9±6.2	122.5±4.7	-42.3 (-49.1 to -35.5) ^b	11.2 (-3.0 to 25.3)
TG, mg/dL				
Add-on (<i>n</i> =207)	160.8±8.1	141.0±5.3	-17.8 (-25.6 to -9.9) ^b	-
MET (<i>n</i> =58)	177.4±19.7	140.8±11.4	-26.8 (-42.0 to -11.7) ^b	-
MET+SU (<i>n</i> =19)	139.5±11.4	151.3±18.6	-0.7 (-28.8 to 27.4)	-26.1 (-69.3 to 17.1)
MET+SU+DPP4i (<i>n</i> =52)	148.0±14.8	132.8±8.6	-22.7 (-39.3 to -6.2)	-4.1 (-34.5 to 26.3)
Insulin (<i>n</i> =78)	160.9±12.2	143.9±8.4	-16.9 (-29.9 to -3.8) ^b	-10.0 (-37.0 to 17.1)
HDL-C, mg/dL				
Add-on (<i>n</i> =207)	45.7±0.8	46.4±0.7	0.8 (-0.2 to 1.7)	-
MET (<i>n</i> =58)	46.2±1.5	48.5±1.1	2.5 (0.7 to 4.3) ^b	-
MET+SU (<i>n</i> =19)	48.9±2.4	49.0±2.2	1.3 (-2.0 to 4.7)	1.2 (-4.0 to 6.3)
MET+SU+DPP4i (<i>n</i> =52)	43.2±1.9	43.4±1.4	-0.8 (-2.8 to 1.2)	3.3 (-0.3 to 6.9)
Insulin (<i>n</i> =78)	46.2±1.2	46.1±1.2	0.0 (-1.5 to 1.5)	2.5 (-0.8 to 5.7)
LDL-C, mg/dL				
Add-on (<i>n</i> =207)	81.6±1.6	81.0±1.7	0.9 (-3.7 to 1.9)	-
MET (<i>n</i> =58)	84.2±3.4	87.0±3.4	3.9 (-1.4 to 9.2)	-
MET+SU (<i>n</i> =19)	76.3±4.4	72.8±3.0	-5.9 (-15.6 to 3.9)	9.7 (-5.2 to 24.7)
MET+SU+DPP4i (<i>n</i> =52)	82.3±2.7	79.0±3.0	-3.0 (-8.7 to 2.7)	6.9 (-3.6 to 17.4)
Insulin (<i>n</i> =78)	80.4±2.7	79.7±3.0	-1.3 (-5.8 to 3.2)	5.2 (-4.2 to 14.6)
Body weight, kg				
Add-on (<i>n</i> =207)	74.1±1.5	72.3±1.5	-1.9 (-2.4 to -1.5) ^b	-
MET (<i>n</i> =58)	79.2±3.0	77.2±2.9	-1.8 (-2.6 to -1.0) ^b	-
MET+SU (<i>n</i> =19)	69.6±5.5	68.0±5.2	-1.7 (-3.4 to -0.1) ^b	-0.1 (-2.5 to 2.4)
MET+SU+DPP4i (<i>n</i> =52)	73.2±2.8	71.5±2.5	-2.1 (-2.9 to -1.3) ^b	0.3 (-1.3 to 1.9)
Insulin (<i>n</i> =78)	71.2±2.3	69.5±2.3	-1.9 (-2.7 to -1.1) ^b	0.1 (-1.4 to 1.6)
SBP, mm Hg				
Add-on (<i>n</i> =207)	131.3±1.0	126.5±1.0	-4.2 (-5.9 to -2.6) ^b	-
MET (<i>n</i> =58)	133.5±1.9	129.7±1.9	-2.7 (-5.7 to 0.3)	-
MET+SU (<i>n</i> =19)	127.4±2.7	122.1±2.7	-7.3 (-12.4 to -2.1)	4.6 (-3.6 to 12.7)
MET+SU+DPP4i (<i>n</i> =52)	127.2±2.0	124.5±1.9	-4.7 (-8.1 to -1.3)	2.0 (-4.2 to 8.2)
Insulin (<i>n</i> =78)	133.3±1.7	126.3±1.6	-6.0 (-8.7 to -3.3) ^b	3.3 (-2.1 to 8.8)
DBP, mm Hg				
Add-on (<i>n</i> =207)	78.4±0.7	77.1±1.0	-1.0 (-2.5 to 0.4)	-
MET (<i>n</i> =58)	83.0±1.2	83.4±2.5	1.9 (-1.3 to 5.2)	-
MET+SU (<i>n</i> =19)	77.8±2.5	76.8±2.8	-1.3 (-6.6 to 4.1)	3.2 (-5.2 to 11.7)
MET+SU+DPP4i (<i>n</i> =52)	78.1±1.3	76.7±1.4	-1.6 (-5.1 to 2.0)	3.5 (-3.0 to 10.0)
Insulin (<i>n</i> =78)	75.7±1.2	72.7±1.2	-4.1 (-6.9 to -1.2) ^b	6.0 (0.0 to 12.0)

Values are presented as mean ± standard error.

FPG, fasting plasma glucose; LS, least square; CI, confidence interval; MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase 4 inhibitor; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.

^aDifference in the LS mean change, which was calculated as compared to adding MET in add-on group and switching from DPP4i in switch group,

^b*P*<0.05 from baseline in overall patients and each treatment subgroup.